These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34323910)

  • 21. Mitochondrion-Directed Nanoparticles Loaded with a Natural Compound and a microRNA for Promoting Cancer Cell Death via the Modulation of Tumor Metabolism and Mitochondrial Dynamics.
    Lo YL; Wang CS; Chen YC; Wang TY; Chang YH; Chen CJ; Yang CP
    Pharmaceutics; 2020 Aug; 12(8):. PubMed ID: 32796618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression.
    He XY; Ren XH; Peng Y; Zhang JP; Ai SL; Liu BY; Xu C; Cheng SX
    Adv Mater; 2020 Apr; 32(17):e2000208. PubMed ID: 32147886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
    Park MY; Jung MH; Eo EY; Kim S; Lee SH; Lee YJ; Park JS; Cho YJ; Chung JH; Kim CH; Yoon HI; Lee JH; Lee CT
    Oncotarget; 2017 May; 8(22):36331-36338. PubMed ID: 28422737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly Uniform Synthesis of Selenium Nanoparticles with EGFR Targeting and Tumor Microenvironment-Responsive Ability for Simultaneous Diagnosis and Therapy of Nasopharyngeal Carcinoma.
    Huang J; Huang W; Zhang Z; Lin X; Lin H; Peng L; Chen T
    ACS Appl Mater Interfaces; 2019 Mar; 11(12):11177-11193. PubMed ID: 30821437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
    Xu Y; Liu R; Dai Z
    Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.
    Hoppmann S; Qi S; Miao Z; Liu H; Jiang H; Cutler CS; Bao A; Cheng Z
    J Biol Inorg Chem; 2012 Jun; 17(5):709-18. PubMed ID: 22418921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes.
    Zhen S; Liu Y; Lu J; Tuo X; Yang X; Chen H; Chen W; Li X
    Hum Gene Ther; 2020 Mar; 31(5-6):309-324. PubMed ID: 31973584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy.
    Liu Q; Wang C; Zheng Y; Zhao Y; Wang Y; Hao J; Zhao X; Yi K; Shi L; Kang C; Liu Y
    Biomaterials; 2020 Nov; 258():120275. PubMed ID: 32798741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation and characterization of a human oral squamous carcinoma cell line SCC-9 with CRISPR/Cas9-mediated deletion of the p75 neurotrophin receptor.
    Huang P; Tong D; Sun J; Li Q; Zhang F
    Arch Oral Biol; 2017 Oct; 82():223-232. PubMed ID: 28654784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
    Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
    Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk.
    Sun T; Patil R; Galstyan A; Klymyshyn D; Ding H; Chesnokova A; Cavenee WK; Furnari FB; Ljubimov VA; Shatalova ES; Wagner S; Li D; Mamelak AN; Bannykh SI; Patil CG; Rudnick JD; Hu J; Grodzinski ZB; Rekechenetskiy A; Falahatian V; Lyubimov AV; Chen YL; Leoh LS; Daniels-Wells TR; Penichet ML; Holler E; Ljubimov AV; Black KL; Ljubimova JY
    Cancer Res; 2019 Mar; 79(6):1239-1251. PubMed ID: 30659021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced Cytosolic Delivery and Release of CRISPR/Cas9 by Black Phosphorus Nanosheets for Genome Editing.
    Zhou W; Cui H; Ying L; Yu XF
    Angew Chem Int Ed Engl; 2018 Aug; 57(32):10268-10272. PubMed ID: 29939484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
    Kim SM; Yang Y; Oh SJ; Hong Y; Seo M; Jang M
    J Control Release; 2017 Nov; 266():8-16. PubMed ID: 28916446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
    Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
    Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
    Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Special Focus Issue Part II: Recruitment of solid lipid nanoparticles for the delivery of CRISPR/Cas9: primary evaluation of anticancer gene editing.
    Akbaba H; Erel-Akbaba G; Senturk S
    Nanomedicine (Lond); 2021 May; 16(12):963-978. PubMed ID: 33970666
    [No Abstract]   [Full Text] [Related]  

  • 40. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
    Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.